A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of MabThera/Rituxan in patients with
relapsed low-grade centroblastic centrocytic non-Hodgkin's lymphoma. Patients will receive
once-weekly intravenous MabThera/Rituxan for 4 weeks; responding patients will be treated a
second time in case of relapse (defined as progression after complete or partial response).
The anticipated time on study treatment is <3 months.